Lista de obras - David Ross - Dominio Público Uruguay

A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia

artículo científico publicado en 2014

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.

artículo científico publicado en 2017

A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone.

artículo científico publicado en 2015

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis

artículo científico publicado en 2018

Acute myeloid leukaemia presenting as galactorrhoea

scientific article published on 01 October 2007

Apparent 'JAK2-negative' polycythaemia vera due to compound mutations in exon 14.

artículo científico publicado en 2016

Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma

artículo científico publicado en 2004

BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management

artículo científico publicado en 2012

BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia.

artículo científico publicado en 2016

Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.

artículo científico publicado en 2016

Cancer treatment with kinase inhibitors: what have we learnt from imatinib?

artículo científico publicado en 2004

Changing incidence of myeloproliferative neoplasms in Australia, 2003-2014

scientific article published on 12 February 2019

Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia

artículo científico publicado en 2020

Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient.

artículo científico publicado en 2011

Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders

artículo científico publicado en 2008

Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene

artículo científico publicado en 2015

Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients

artículo científico publicado en 2013

Do we have to kill the last CML cell?

artículo científico publicado en 2010

Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features

artículo científico publicado en 2011

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

artículo científico publicado en 2018

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.

artículo científico publicado en 2013

Extramedullary relapse of chronic myeloid leukemia in blast crisis: more questions than answers.

artículo científico publicado en 2009

Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification.

artículo científico publicado en 2009

Giant parallel tubular arrays in T lymphocytes

scientific article published on 01 January 2013

How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia.

artículo científico publicado en 2014

How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?

artículo científico publicado en 2008

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

scientific article published on 27 March 2019

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

artículo científico publicado en 2006

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

artículo científico publicado en 2018

Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera.

artículo científico publicado en 2016

Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?

artículo científico

Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission

artículo científico publicado en 2019

Moving treatment-free remission into mainstream clinical practice in CML.

artículo científico publicado en 2016

Need to minimize bias when surveying patient attitudes to stopping cml treatment

artículo científico publicado en 2014

Novel protein C gene mutation in a compound heterozygote resulting in catastrophic thrombosis in early adulthood: diagnosis and long-term treatment with subcutaneous protein C concentrate

scientific article published on 24 June 2015

Patient perceptions of treatment-free remission in chronic myeloid leukemia.

artículo científico publicado en 2017

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

artículo científico publicado en 2010

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

artículo científico publicado en 2014

Peripheral neuropathy on imatinib treatment for chronic myeloid leukaemia: suspected adverse drug interaction with amlodipine

artículo científico publicado en 2009

Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia

artículo científico publicado en 2007

Practical management of myelofibrosis with ruxolitinib.

artículo científico publicado en 2015

Practical management of patients with myelofibrosis receiving ruxolitinib

artículo científico publicado en 2013

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

artículo científico publicado en 2014

Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia.

artículo científico publicado en 2010

Reply to 'What do we mean by sensitivity when we talk about detecting minimal residual disease?' by Steinbach and Debatin.

artículo científico publicado en 2008

Responses to pomalidomide and placebo in myelofibrosis-related anaemia.

artículo científico publicado en 2016

Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease

artículo científico publicado en 2008

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

artículo científico publicado en 2013

Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.

artículo científico publicado en 2010

Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR

artículo científico publicado en 2016

Success is built on failures: tackling the challenge of ponatinib failure

artículo científico publicado en 2018

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

artículo científico publicado en 2014

The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia

scientific article published on 11 January 2019

There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge

scientific article published on 10 November 2020

Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.

artículo científico publicado en 2017

Treatment-free remission after stopping second-line dasatinib.

artículo científico publicado en 2015

Treatment-free remission in patients with chronic myeloid leukaemia

scientific article published on 06 May 2020

Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia

artículo científico

Lista de obras de David Ross

A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.

A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone.

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis

Acute myeloid leukaemia presenting as galactorrhoea

Apparent 'JAK2-negative' polycythaemia vera due to compound mutations in exon 14.

Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma

BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management

BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia.

Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.

Cancer treatment with kinase inhibitors: what have we learnt from imatinib?

Changing incidence of myeloproliferative neoplasms in Australia, 2003-2014

Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia

Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient.

Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders

Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene

Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients

Do we have to kill the last CML cell?

Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.

Extramedullary relapse of chronic myeloid leukemia in blast crisis: more questions than answers.

Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification.

Giant parallel tubular arrays in T lymphocytes

How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia.

How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera.

Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?

Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission

Moving treatment-free remission into mainstream clinical practice in CML.

Need to minimize bias when surveying patient attitudes to stopping cml treatment

Novel protein C gene mutation in a compound heterozygote resulting in catastrophic thrombosis in early adulthood: diagnosis and long-term treatment with subcutaneous protein C concentrate

Patient perceptions of treatment-free remission in chronic myeloid leukemia.

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

Peripheral neuropathy on imatinib treatment for chronic myeloid leukaemia: suspected adverse drug interaction with amlodipine

Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia

Practical management of myelofibrosis with ruxolitinib.

Practical management of patients with myelofibrosis receiving ruxolitinib

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia.

Reply to 'What do we mean by sensitivity when we talk about detecting minimal residual disease?' by Steinbach and Debatin.

Responses to pomalidomide and placebo in myelofibrosis-related anaemia.

Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.

Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR

Success is built on failures: tackling the challenge of ponatinib failure

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia

There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge

Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.

Treatment-free remission after stopping second-line dasatinib.

Treatment-free remission in patients with chronic myeloid leukaemia

Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia